Yenyou Zheng Net Worth

The estimated Net Worth of Yenyou Zheng is at least $822 dollars as of 11 May 2023. Yenyou Zheng owns over 858 units of Novabay Pharmaceuticals Inc stock worth over $822 and over the last 4 years he sold NBY stock worth over $0. In addition, he makes $0 as Independent Director at Novabay Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Yenyou Zheng NBY stock SEC Form 4 insiders trading

Yenyou has made over 2 trades of the Novabay Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 858 units of NBY stock worth $411 on 11 May 2023.

The largest trade he's ever made was exercising 30,000 units of Novabay Pharmaceuticals Inc stock on 21 May 2022 worth over $14,379. On average, Yenyou trades about 4,408 units every 51 days since 2020. As of 11 May 2023 he still owns at least 1,716 units of Novabay Pharmaceuticals Inc stock.

You can see the complete history of Yenyou Zheng stock trades at the bottom of the page.

Yenyou Zheng biography

Dr. Yenyou Zheng, Ph.D. is Independent Director of the Company. He has served as the Director of Business Development of Spartan Securities Group, Ltd. since 2014. Dr. Zheng’s experience includes providing innovative financial solutions and consulting services for initial public offering underwriting and investment banking as well as corporate financing solutions with a particular focus on Chinese companies listed overseas. Dr. Zheng previously was a financial advisor for various Canadian public companies including: P & P Ventures Inc. (TSX-V: PPV.H) where he served as president and a director; Damon Capital Corp (TSX-V: DAM.H) where he served as Chief Financial Officer and a director; and Cantronic Systems Inc. (TSX-V: CTS) where he served as a director and chair of the audit committee. Dr. Zheng received a Ph.D in physics from Flinders University of South Australia.

How old is Yenyou Zheng?

Yenyou Zheng is 63, he's been the Independent Director of Novabay Pharmaceuticals Inc since 2019. There are 1 older and 8 younger executives at Novabay Pharmaceuticals Inc. The oldest executive at Novabay Pharmaceuticals Inc is Paul Freiman, 81, who is the Independent Director.

What's Yenyou Zheng's mailing address?

Yenyou's mailing address filed with the SEC is C/O NOVABAY PHARMACEUTICALS, INC., 2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608.

Insiders trading at Novabay Pharmaceuticals Inc

Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over $3,799,939 worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth $26,237,091 . The most active insiders traders include Pharma (Singapore) Pte. Ltd..., Pioneer Pharma Holdings Ltd..., and Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of $127,779. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth $411.

What does Novabay Pharmaceuticals Inc do?

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

Complete history of Yenyou Zheng stock trades at Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals Inc executives and stock owners

Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Justin M. Hall Esq.,
  Pres, CEO, Gen. Counsel, Chief Compliance Officer, Corp. Sec. & Director
• Justin Hall,
  President, Chief Executive Officer, Director
• Andrew Jones,
  Chief Financial Officer, Treasurer
• Swan Sit,
  Independent Director
• Yenyou Zheng,
  Independent Director
• Paul Freiman,
  Independent Director
• Mijia Wu,
  Director
• Xinzhou Li,
  Director
• Dr. Jeffrey Kunin M.D.,
  Pres of DERMAdoctor
• Dr. Audrey Kunin M.D.,
  Chief Product Officer
• Yongxiang Zheng,
  Director
• Julie Garlikov,
  Director
• Wang Xu,
  NEO - Sr Mgr and Controller
• Lewis J Stuart,
  Chief Commercial Officer
• Yanbin Liu,
  Director
• Jason Philip Raleigh,
  Interim CFO and Treasurer
• Xiaoyan Liu,
  Director
• Gail J Maderis,
  Director
• Todd Erik Zavodnick,
  Director
• Pharma (Singapore) Pte. Ltd...,
  10% owner
• T. Alex Mc Pherson,
  Director
• Thomas J Paulson,
  Chief Financial Officer
• Yonghao Ma,
  Director
• Jian Ping Fu,
  10% owner
• Massimo Radaelli,
  Director
• Mark M Sieczkarek,
  Director
• Pharma (Hong Kong) Co Ltd P...,
  10% owner
• John Joseph Mc Govern,
  Int Pres, CEO, CFO & Treasurer
• John James O'reilly,
  Chief Financial Officer
• Colin Scott,
  VP, Clinical Research & Dev't
• Keith R Bley,
  SVP Product Development
• Pioneer Pharma Holdings Ltd...,
  10% owner
• Roy J Wu,
  SVP Bus & Corp Development
• David W. Stroman,
  SVP, Ophthalmic Product Devt.
• Tony D.S. Wicks,
  Director
• Anthony Dailley,
  Director
• Robert R. Tufts,
  Director
• Charles Cashion,
  Director
• Behzad Khosrovi,
  VP, Research & Dev't
• Ramin Najafi,
  Chief Executive Officer
• Area Pioneer Pharma Co., Lt...,
  10% owner
• Ramin Najafi Family Trust D...,
  Chief Executive Officer
• Mark Brian Anderson,
  CSO
• Harry F Jr Hixson,
  Director
• Russell A. Hoon,
  Senior Vice President
• Xiaopei Wang,
  
• Jeffrey Kunin,
  President, DERMAdoctor, LLC
• Audrey Kunin,
  Chief Product Officer